Update on Diabetes TherapyDespite evidence that optimal glycemic control can help reduce disease progression and complications, most patients do not achieve recommended treatment goals.
Study Finds Oral Syringes Better for Liquid Pediatric MedsA randomized controlled study has found that oral syringes are more accurate than dosing cups when parents measure doses of liquid medications for their children.
Pharmacist involvement key in heart risk screeningPharmacists’ involvement in cardiovascular risk screening resulted in referrals to physicians for patients who were under-diagnosed.
Eligible infants not getting rotavirus vaccineResearchers found that estimated coverage for RV at 19 to 35 months of age lags behind the other vaccines recommended at ages two, four, and six.
Why Remicade biosimilar sales will grow in the U.S.Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions.
What executives must know to combat rising drug spendIn today’s healthcare landscape, few things better define the role of a managed healthcare executive than managing the industry’s constant changes.
Anticoagulant therapies
The Power of a NameA new study suggests that the name of a biosimilar product could influence pharmacist confidence levels when dispensing a biosimilar in place of a reference biologic.
A Triple Hitter in One Blast: COPD Lessons from TRILOGYPatients with severe COPD are likely to suffer frequent disease exacerbations and a reduced quality of life.
QD Fluticasone-Vilanterol combo reduces COPD exacerbationsIn patients with COPD who have a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with fewer exacerbations than usual care without a greater risk of serious adverse events